Alnylam Pharmaceuticals
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Inclusion Criteria: * Documented diagnosis of AHP, per physician's determination Exclusion Criteria: * Currently enrolled in a clinical trial for any investigational agent